KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Debt: 2009-2024

Historic Non-Current Debt for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $51.9 million.

  • Ionis Pharmaceuticals' Non-Current Debt rose 24.11% to $51.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $51.9 million, marking a year-over-year increase of 24.11%. This contributed to the annual value of $51.9 million for FY2024, which is 24.11% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Non-Current Debt of $51.9 million as of FY2024, which was up 24.11% from $41.8 million recorded in FY2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Non-Current Debt peaked at $60.0 million during FY2020, and registered a low of $16.0 million during FY2022.
  • Its 3-year average for Non-Current Debt is $36.6 million, with a median of $41.8 million in 2023.
  • Its Non-Current Debt has fluctuated over the past 5 years, first slumped by 73.25% in 2022, then skyrocketed by 161.92% in 2023.
  • Yearly analysis of 5 years shows Ionis Pharmaceuticals' Non-Current Debt stood at $60.0 million in 2020, then dropped by 0.45% to $59.7 million in 2021, then slumped by 73.25% to $16.0 million in 2022, then soared by 161.92% to $41.8 million in 2023, then grew by 24.11% to $51.9 million in 2024.